Navigation Links
deCODE Announces Positive Topline Results for Phase I Study of,DG051 for the Prevention of Heart Attack

REYKJAVIK, Iceland, May 01, 2007 /PRNewswire-FirstCall/ -- deCODE genetics today announced positive top-line results from its Phase I multiple dose clinical trial of DG051, which the company is developing for the prevention of heart attack. In the study, a randomized, double-blind, multi- dose, ascending dose, placebo-controlled clinical trial, a total of 40 healthy subjects were exposed to DG051 at doses up to 320mg per day for seven days. Building upon the positive results seen in the Phase I single dose study completed at the end of last year, key results were:

Safety and tolerability: DG051 was well tolerated at all dose levels tested, with no serious adverse events reported.

Dose-dependent reduction of leukotriene B4 (LTB4): DG051 was shown to reduce LTB4 production in a dose-dependent manner, with a peak reduction of more than 70% versus baseline after 7 days of treatment.

Pharmacokinetic profile: DG051 was found to have good bioavailability, with low variability between subjects. With a terminal half-life of approximately 9 hours and measurable concentrations at 24 hours after dosing, DG051 has a pharmacokinetic profile suitable for once-a-day dosing.

"The results of our Phase I trials show DG051 to be well tolerated and to provide a potent means of reining in the activity of the pathway our research has shown to modulate risk of heart attack. This latest study also provides us with pharmacodynamic data suggesting that we may be able to achieve a high steady-state reduction in LTB4 production with a dose in the middle of the range we have tested, and we look forward to entering DG051 into Phase II trials later this year," said Kari Stefansson, CEO of deCODE.

About DG051

DG051 is a first-in-class, small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H) discovered by deCODE's chemistry unit and being developed for the prevention of heart attack. LTA4H is encod
'"/>




Page: 1 2 3

Related medicine technology :

1. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:9/18/2014)... 2014 This BCC Research report discusses the medical device ... growth and size, and opportunities for different devices and regions. ... Patent analysis in the report focuses on technological trends in ... Europe and Japan . ... the global medical device technologies market. - Analyze market structure, ...
(Date:9/18/2014)...  Iliad Neurosciences, Inc., a company focused on the ... Spectrum Disorders (ASD) announced today that it has entered ... for The State University of New York. ... to identify an abnormality in folate transport to the ... expected to be available for research use by physicians ...
(Date:9/18/2014)... , September 18, 2014 ... audience, has updated the incredibly successful Serialisation Countdown calendar ... interactive PDF, available at pharmaserialisation.com shows the ... which they will be coming into force. ... longer a matter of "if", but "when" they will ...
Breaking Medicine Technology:Medical Devices: Technologies and Global Markets 2Medical Devices: Technologies and Global Markets 3Medical Devices: Technologies and Global Markets 4Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 2
... MADISON, N.J., Jan. 6, 2012 Quest Diagnostics Incorporated ... of diagnostic testing, information and services, announced today the ... Health System to acquire S.E.D. Medical Laboratories. Under the ... assets of S.E.D. Medical Laboratories and will manage in-patient ...
... 2012 In preparation for meetings starting Monday, ... scheduled for 10:00 a.m. Thursday, January 12 at ... Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR ) ... the fourth quarter 2011:       -Approximately 935-950 ...
Cached Medicine Technology:Quest Diagnostics Completes Acquisition of S.E.D. Medical Laboratories 2Questcor Pharmaceuticals Reports Strong Finish to 2011 2Questcor Pharmaceuticals Reports Strong Finish to 2011 3Questcor Pharmaceuticals Reports Strong Finish to 2011 4Questcor Pharmaceuticals Reports Strong Finish to 2011 5Questcor Pharmaceuticals Reports Strong Finish to 2011 6
(Date:9/18/2014)... Georgia (PRWEB) September 18, 2014 Technology ... the winners of its 2nd TAG Social Savvy Awards ... Junior Achievement’s Chick-fil-A Foundation Discovery Center in Downtown Atlanta. ... media. , Turner Sports was honored with the ... This year’s event also recognized innovators in 6 other ...
(Date:9/18/2014)... Researchers are trying to learn more about a condition ... in young athletes. In people with sickle cell ... muscle breakdown that can lead to kidney damage and ... players in the United States collapsed and died during ... trait. "More student-athletes with sickle cell trait have ...
(Date:9/18/2014)... NC (PRWEB) September 18, 2014 October ... also Domestic Violence Awareness Month. And the Centers for ... tells a scary story. , According to the CDC ... fourth of men in the U.S. experience some form ... intimate relationship. The same survey shows that about half ...
(Date:9/18/2014)... September 18, 2014 Fall is here, and ... bike is here to stay. Just as the temperature ... up, says Bikesdirect.com . Women across America are discovering ... calls a city bike. , Windsor Bicycles USA says, "City ... are higher than the typical road bike, and the seat ...
(Date:9/18/2014)... technology has shed new light on how certain symptoms ... according to a new study. PTSD is ... range of debilitating symptoms, such as flashbacks to a ... and avoiding certain situation and people, according to background ... opioid receptor in the brain linked to emotion that ...
Breaking Medicine News(10 mins):Health News:Winners Honored at 2014 TAG Social Savvy Awards 2Health News:Winners Honored at 2014 TAG Social Savvy Awards 3Health News:Scientists Studying Sickle Cell Trait 2Health News:What you should know about domestic violence 2Health News:What you should know about domestic violence 3Health News:What you should know about domestic violence 4Health News:What you should know about domestic violence 5Health News:City Bikes Become a Must-have for Women This Fall, Says Bikesdirect.com 2Health News:Research Shows Possible Neurological Patterns for PTSD Symptoms 2Health News:Research Shows Possible Neurological Patterns for PTSD Symptoms 3
... WASHINGTON, DC) The Society for Cardiovascular Angiography and ... announced today that they will hold a unified interventional ... meeting will be known as The SCAI Annual Scientific ... be held concomitantly with the ACC Annual Scientific Session. ...
... men who have sex with men (MSM) in New York City, ... among MSM under age 30 have increased by 33% during the ... to almost 500 in 2006. New diagnoses have doubled among MSM ... under-30 group now accounts for 44% of all new diagnoses among ...
... Sept. 11 The Department of,Public Welfare today ... system whose personal information may have been contained,on ... office building in Harrisburg., The burglary remains ... the information on the stolen computers has been ...
... PT. RICHMOND, Calif., Sept. 11 Transcept,Pharmaceuticals, Inc., ... from proven CNS drugs, today announced,that Glenn A. ... present at the UBS 2007 Global Life Sciences ... Tuesday, September 25, 2007 at 4:00 p.m. ET. ...
... Is the Most Comprehensive Ever, NEW YORK, ... research,-- the most comprehensive ever conducted -- once ... safe, even among its heaviest users. The ... Use,Levels, Regulations, and Toxicological and Epidemiological Studies,",published in ...
... opportunities for immigrants to obtain legal residency and citizenship ... access to health care, according to an article published ... Affairs. , Immigrants now make up 12 percent ... lead author of the article and a policy researcher ...
Cached Medicine News:Health News:SCAI and ACC announce new interventional cardiology meeting 2Health News:New HIV diagnoses rising in New York City among young men who have sex with men 2Health News:New HIV diagnoses rising in New York City among young men who have sex with men 3Health News:New HIV diagnoses rising in New York City among young men who have sex with men 4Health News:PA Department of Public Welfare Begins Outreach to Medical Assistance Consumers Following Burglary at State Office Building 2Health News:New Study of Aspartame Research Reaffirms Safety, Even Among Heaviest Users 2Health News:New Study of Aspartame Research Reaffirms Safety, Even Among Heaviest Users 3Health News:RAND researchers offer options to improve immigrant health care quality, access 2
The MULTI-LINK RX PENTA Coronary Stent Systems with new ACCESS-LINK Stent Design are indicated for improving coronary luminal diameter....
Now available in 2.75-mm diameters, the S660 small vessel coronary stent expands your treatment options for accurate sizing and precision stenting....
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC)....
... EVS has an ergonomic stapler ... mechanism which requires a single ... locks onto the target vessel ... site before, during and after ...
Medicine Products: